

Index

- AA-5-HT 156
 absent-mindedness 23
 ACEA 92
 acetylcholine 96
 acetylcholinesterase inhibitor 95
 2-acyl-glycerol 90
 β 2 adrenergic receptor 202
 adverse effect 258, 260
 adverse event 255, 256
 AEA membrane transporter (AMT)
 68
 ageing 75
 ajulemic acid 155
 alkaline phosphatase activity 203
 allodynia 153, 252
 Alzheimer's disease (AD) 12, 37,
 38, 59, 79, 89, 95, 101, 121, 132
 AM-251 184, 188, 195
 AM-281 32
 AM-356 32
 AM-374 156
 AM-404 157
 AM-630 32
 AM-1241 32
 AM-2233 32
 γ -aminobutyric acid (GABA) 16
 amphetamine 193
 β -amyloid peptide 95
 β -amyloid precursor protein 95
 amyotrophic lateral sclerosis (ALS)
 79, 89, 99–101
 analgesia 150
 ananda 4
 Anandakanda 3
 anandamide (*N*-arachidonylethanol-
 amine, AEA) 17, 26, 67, 68,
 113–115, 119, 122, 13, 156, 184,
 185, 187, 189, 234, 259
 angiogenesis 15, 170
 animal models of HD 91
 anorexia 12, 220
 anti-cancer effect of cannabidiol 58
 anti-convulsant effect of cannabidiol
 13, 48
 anti-emetics 184–186, 195
 anti-emetic effect of cannabidiol 57
 anti-emetic effect of
 tetrahydrocannabinol 57
 anti-inflammatory activity of
 cannabidiol 55
 anti-inflammatory potential of
 cannabinoid agonists 86
 anti-neoplastic activity of Δ^9 -THC
 166
 anti-nociception and cannabidiol 55
 antioxidant activity of cannabidiol
 13, 54, 242
 anti-proliferative effects of
 cannabinoids 81
 antipsychotic activity of cannabidiol
 53
 anti-tumour effect of cannabidiol
 28, 58
 ANV 184, 186, 192, 195
 anxiety and cannabidiol 52
 anxiety, agonists, HU210 142
 anxiety, agonists, Δ^9 -THC 142
 anxiety, anandamide hydrolysis 143
 anxiety, anandamide hydrolysis,
 (FAAH) inhibitors 143
 anxiety, antagonists (SR-141716)
 142
 anxiety, anxiolytic effects,
 cannabidiol 141
 anxiety, anxiolytic effects, mono-
 methyl cannabidiol 141

- anxiety, anxiolytic effects, 2-piny-5-dimethylheptyl 141
 anxiety, behavioral tests, conditioned taste aversion 141
 anxiety, behavioral tests, defensive withdrawal test 142
 anxiety, behavioral tests, elevated-plus maze 141
 anxiety, behavioral tests, lick-suppression test 141
 anxiety, behavioral tests, two-compartment black and white box test 142
 anxiety, behavioral tests, ultrasonic emission test 143
 anxiety, behavioral tests, Visual Analogue Mood Scale (VAMS) 144
 anxiety, brain imaging 145
 anxiety, brain regions, amygdala 145
 anxiety, brain regions, cingulate gyrus 145
 anxiety, brain regions, parahippocampal activity 145
 anxiety, CB₁-knockout mouse 143
 anxiety, clinical trials, Marinol 146
 anxiety, clinical trials, Nabilone 146
 anxiety, clinical trials, Sativex[®] 146
 apomorphine 187
 apoptosis 28, 75, 88, 170
 appetite and cannabidiol 58, 219
 appetite stimulation 13
 application site reaction 255
 2-arachidonoyl glycerol (2-AG) 26, 156, 184, 189, 190, 202, 259
 arachidonoyl serotonin 156
 arachidonoyl-serine (ARA-S) 234
 asthma 10, 13
 ataxia 98
 Atharvaveda 2, 12
 autoimmune disease 97
 aversive memory 13
 axonal degeneration 98
 Ayurveda 1
 Ayurvedic medicine 1
 A β deposition 95, 96
 A β -enriched neuritic plaques 96
 A β -induced neurotoxicity 97
 bague 5
 basal ganglia 91, 94, 96, 99
 behavioral sensitization 209
 bhang, bhanga 2, 3, 4, 6
 bladder dysfunction 252, 253, 259
 bladder-related symptoms 247
 blood-brain-barrier breakdown 83
 blood-brain-barrier disruption 86
 BMS-1 157
 body temperature 81
 bone formation 201–203
 bone mass 201–204
 bone remodeling 201–203
 bone resorption 201, 203
 botanical drug products (BDP) 237, 243, 260
 botanical drug substance (BDS) 241–243
 botanical raw material (BRM) 238, 240, 241, 243, 259
 brachial plexus avulsion 247, 251, 253
 brachial plexus injury 255
 bradykinesia 93, 94
 brain damage 79
 bronchodilation 13
 calcium channel 84
 calcium influx 94
 calpain 83, 92
 cAMP-response element (CRE) 73
 cancer 37, 58, 154, 165, 167, 233
 cancer cell proliferation 167
 cancer pain 233
 cannabichromene (CBC) 12, 16, 25, 236, 242, 243
 cannabicyclol 25
 cannabidiol structure 47
 cannabigerol (CBG) 25, 236, 242, 243

- cannabinoid agonist 190, 219
- cannabinoid ratio 259
- cannabinoid tolerance 208
- Cannabis indica* 8
- Cannabis sativa* L. 236, 238, 244
- caryophyllene 16
- caspase 3 83, 92, 97
- caspase 83
- cat 187, 188
- catalase 84
- CB₁ agonist noladin ether 203
- CB₁ antagonist 184, 194, 195
- CB₁ deficient mouse 90, 99, 202, 203
- CB₁ receptor 67, 84, 88, 90–92, 99, 184, 185, 189, 194, 195, 233
- CB₁ receptor antagonist 185, 189
- CB₁^{-/-} mouse 112, 118–125, 129
- CB₁-knockout mouse 213
- CB₁-selective antagonist 32
- CB₂ activation 203
- CB₂ agonist HU-308 203
- CB₂ deficient mouse 203
- CB₂ receptor 80, 87, 96–98, 100, 233
- CB₂ receptor antagonist 189
- CB₂ signaling 203, 204
- CB₂-selective cannabinoid receptor ligand 34
- central neuropathic pain (CNP) 247, 249, 251–253
- cerebral ischemia 88, 90
- charas 4, 6
- chemotherapy 15
- chemotherapy, ANV 192
- chemotherapy, emetic episodes 183
- chemovar 237, 239, 240
- cholera 15
- choreic movements 91
- chronic refractory pain 247
- chronic relapsing experimental autoimmune encephalomyelitis (CREAE) 98
- cisplatin 183–185, 187–192
- classification of cannabinoids 234
- clone 239
- closed head injury 80, 83, 90
- cocaine 14
- complex II deficiency 92
- conditioned avoidance 18, 193
- conditioned freezing 122
- conditioned gaping 192, 193
- conditioned rejection 195
- conditioned rejection reaction 193
- conditioned taste avoidance 193
- constipation 12, 23
- convulsion 10
- copper/zinc superoxide dismutase 1 (SOD-1) 100
- CP-55,940 27, 189
- Crohn's disease 15
- Cryptotis parva* 187
- cyclophosphamide 194
- p-cymene 16
- cytotoxic levels of Ca²⁺ 83
- dandruff 16
- demyelination 86, 97
- depolarization-induced suppression of inhibition (DSI) 128, 129
- dexanabinol (HU-211) 82, 83, 90, 100, 142
- diagnostic marker 75
- diarrhea 13
- dog 187, 188
- dopamine 99
- dose-response relationships of cannabidiol, bell-shaped 53–55, 60
- dronabinol 96, 185, 252
- drug-discrimination 210
- dysentery 11
- dyskinetic state 93
- dysmenorrhea 10, 13, 16
- dystonia and cannabidiol 52, 98
- dysuria 10
- eczema 10, 15
- edema 83
- EDSS 250

- electroencephalogram (EEG) 254
 embryo implantation 68
 emesis across species, effect of
 cannabinoid 187
 emesis and cannabidiol 57
 emesis 57, 184–191
 emetine 187
 endocannabinoid 149, 165, 202, 234
 endocannabinoid degradation 172
 endocannabinoid level 99
 endocannabinoid system 202
 endogenous cannabinoids 25
 endonuclease 83
 endothelium-derived factor 100
 endothelium-derived mediators 87,
 88
 endothelin-1 (ET-1) 87, 100
 entourage effect 26
 epilepsy 12, 48
 estrogen depletion 203
 ET-1 100
 ET-1-induced vasoconstriction 88
 ethanol 214
 excitotoxicity 79, 81, 88, 90–92,
 94, 98–100
 experimental autoimmune
 encephalomyelitis (EAE) 98
 extension study 255
 extract of cannabis 231

 fatty acid amide hydrolase (FAAH)
 68, 69, 96, 149, 156, 184, 235
 FAAH activator 69
 female disorder 23
 ferret 187, 188, 192, 195
 fibrillary tangle 95
 first-pass metabolism 236
 flavonoid 236, 242
 flavor aversion learning 193
 follicle-stimulating hormone (FSH)
 74
 food consumption and cannabidiol
 58
 Fos 150
 fracture risk 201

 G protein 155
 GABA 16, 83, 99, 127, 128
 GABA transmission 83
 ganja 3, 4, 6
 gaping 192–195
 gastritis 12, 15
 General Health Questionnaire-12
 (GHQ-12) 251
 glaucoma 38, 57
 glial cell 80, 86
 gliosis 95
 glucose deprivation 88
 glucose utilization 81
 glutamate 99, 126
 glutamate release 82
 glutamatergic excitotoxicity 88
 glutation 84
 gonorrhea 10
 Good Agricultural Practice (GAP)
 236, 241
 Good Clinical Practice (GCP) 236
 Good Laboratory Practice (GLP)
 236
 Good Manufacturing Practice
 (GMP) 236, 241
 granisetron 191

 haoma-soma 2
 harvest index 238
 head trauma 79, 88
 hemorrhoids 16
 heroin 213
 herpes simplex virus 16
 hippocampal activity 113
 hippocampus 96, 122, 125
 HIV/AIDS 15
 house musk shrew 187, 189
 5-HT₃ agonist 189
 5-HT₃ antagonist 184, 185, 191,
 193, 195
 5-HT₃ receptor antagonist 189, 192
 5-HT₃ receptor 183, 185
 5-HTP 187
 6-hydroxydopamine 94, 95
 5-hydroxytryptamine (5-HT) 187

- HU-210 93, 95, 142, 153, 189, 194
HU-211 86
HU-308 92
HU-320 155
human sperm 74
huntingtin protein 91
Huntington's chorea 37
Huntington's disease (HD) 52, 79, 89, 91, 93, 101
11-hydroxy-tetrahydrocannabinol (11-OH-THC) 232, 236
hyperalgesia 154
hypoxia 88
- IL-1 receptor antagonist 87
IL-1 β -deficient mouse 93
immunomodulatory agent 98
implantation 67
impotence 12, 13, 16
incontinence 16
Indian Hemp Drugs Commission 2, 7, 17
inflammation 39, 55, 79, 85, 90, 92, 94
inflammatory stimuli 93
inhibitors of endocannabinoid degradation 175
inhibitors of endocannabinoid inactivation 172
insanity 8, 10
insomnia 10, 12–14
interleukin (IL)-1 β 85, 93, 95
interleukin (IL)-6 85, 86
interleukin (IL)-10 86
interleukin (IL)-12 86
intoxication 256–258, 260
intoxication-like reaction 256
intraocular pressure and cannabidiol 57
intraocular pressure and tetrahydrocannabinol 57
inwardly rectifying K⁺ channels 84
ionic homeostasis 81
ischemia 79
ischemic episodes 100
ischemic stroke 88
isobolographic analysis 157
itch 15
- jaundice 12, 13
jaya 4
JWH-051 33
- kainate 90
kainate-induced excitotoxicity 80
ketone bodies, production 81
K-*ras* oncogene 168
- L-dopa 93, 94
least shrew 187, 189, 190
leptin 73, 201, 202
levonantradol 185, 234
Leydig cells 74
lice 16
lithium 186, 190–195
lithium chloride 187, 189, 192
long-term depression (LTD) 130, 131
long-term intoxication 257
long-term potentiation (LTP) 120, 126, 129, 130,
low bone mass (LBM) 202
lower urinary tract 16
lower-urinary-tract symptoms 13
lypase 83
- Makhzan-al-Adwiya 6
malaria 16, 23
malonate 92
marijuana 184–186, 189
Marinol[®] 146, 234
materia medica 2
matrix mineralization 203
MDMA 214
memantine 95
memory processing and cognition 96
mesolimbic dopaminergic system 212
metastasis 170

- met-fluoro-anandamide 168
methanandamide 32, 187, 189
(*R*)-methanandamide (AM-356) 32
methylevonantradol 188
2-methylserotonin 187, 189
microglia 87
microglial activation 94
microglial cell 55, 87, 96
microglial cell migration and
cannabidiol 55, 87
microglial cell proliferation and
migration 87
migraine 10, 13, 14
minor cannabinoid 239
miscarriage 72
mitochondrial complex II 93
mitochondrial dysfunction 79, 85,
90, 92, 93
mitogen activated protein kinase
pathway 97
model ANV, shrew 191, 192
mood and overall sense of well-
being 247
morning pain in rheumatoid arthritis
247
morphine 157, 187, 213
mother plant 239
mRNA expression 202
multiple sclerosis (MS) 13, 16, 37,
38, 79, 86, 89, 97, 99, 101, 144,
233, 247, 250, 252–255, 259
muscle relaxation 13
muscle spam 247
- Na⁺/K⁺-ATPase 90
Nabidiolex[®] 242–244
nabilone 185, 187, 188, 234
NADA 156, 259
N-arachidonoyl-dopamine 26, 234
nausea, rat model 192–195
nephritis 39
neuralgia 10
neuritic plaque 95, 96
neurodegenerative diseases 37
neurokinin1 (NK₁) 184
neuropathic pain 13, 233, 247, 252–
255, 259
neuropathy 37
neuroprotection 13, 54
neurotransmission and cannabidiol
50
nicotine 213
nigral dopaminergic neurons 93
3-nitropropionic acid 92
3-nitropropionic acid toxicity 92
NMDA receptor 81, 83, 92, 95, 100
NMDA-induced excitotoxicity 90
N-methyl-D-aspartate (NMDA) 14
N-methylevonantradol 187
NO 85–88, 93, 95, 97, 100
NO donors 74
NO synthase 83, 84, 86
nocturia 16
noladin ether 26, 234, 259
non-cannabinoid fraction 241–243
non-psychoactive cannabinoids 155
noradrenergic signaling 202
nuclear factor-κB (NF-κB) 86
numerical rating scale 249
- obesity 219
OL-135 157
oleamide 26
oligodendrocytes 98
OMDM-1 157
ondansetron 185, 190, 193, 194
opiate sparing 247
opium 11
orexigenic action 91
oromucosal cannabis-based
medicine 16
oromucosal spray 251
osteoblast 201–203
osteoblastic marker gene 202
osteoclast 201, 202
osteoclast differentiation 201, 202
osteocyte 202
osteogenic medium 202
osteoporosis 201, 204
ovariectomy 204

- oxidative cell death 84
oxidative injury 99, 100
oxidative stress 79, 84, 88, 90, 92–94, 100
- pain 37, 39, 149, 252
palmitoylethanolamide 26
Parkinson's disease (PD) 37, 38, 79, 89, 93, 94, 101
Patient's Global Impression of Change (PGIC) 251, 254
peak bone mass 203
periaqueductal gray 150
peripheral cannabinoid receptor (CB₂) 26, 30
peripheral lymphocyte 72
peripheral neuropathic pain 247, 252, 253, 255
peripheral pain 37
peroxidase 84
peroxisome proliferator-activated receptor γ (PPAR γ) 28
phospholipase D (PLD) 68
pigeon 187, 188
 α -pinene 15
placebo 247
postmenopausal osteoporosis 203
premature ejaculation 13
progesterone 73
proinflammatory cytokines 93
protein kinase 83
pruritis 39
psoriasis 15
psychotic illnesses and cannabidiol 53
- quality of life 247, 253, 255
- rabies 14
Rajanighantu 3
Rajavallabha 5
rat 192, 194
rat model of nausea 190
reactive microglia 86
reactive oxygen species 83–85, 97, 100
- reference memory 112, 117
relapse 214
reproductive fluids 72
rheumatic disease 15
rheumatic pain 23
rheumatoid arthritis 13, 15, 259
rigidity 93, 94
riluzole 99
rimonabant 29, 30, 172, 187, 223, 234
- S. murinus* 192, 195
safety 256
Sanskrit 1, 3
Sativex 146, 239, 241, 243–260
Sativex[®], clinical effects 245–247
secondary excitotoxicity 88
self-titration 244, 252, 257, 260
serotonin 99, 185, 190, 194
Sertoli cell 74
sex hormones 68
shrew 188–192, 195
side effect 245, 260
skeletal development 204
sleep, 57, 247
sleep disturbance 247, 251, 253
sleep quality 247, 251, 253, 254
small-molecule antioxidants 84
Soma 2
spasm 252, 253, 254, 259
spasticity 98, 247, 252–254, 259
spasticity in MS 247
spatial tasks 116
spinal cord 97, 98
spinal cord injury 255
spinal motor neurons 99
spontaneous activity and rectal temperature 38
SR-141716 29, 30, 82, 84, 88, 90, 96, 113, 114, 119, 120, 122–124, 129, 172, 184, 187, 189, 194, 195, 213, 221, 223, 234
SR-144528 92, 189
STAT3 73

- sterol 242
striatum 93
stroke 80, 87
stromal cell 201
substantia nigra *pars compacta* 93
substantia nigra *pars reticulata* 83
Suncus murinus 187
Suncus 189, 190, 191
superoxide dismutase 84, 100
superoxide 84
Sushruta Samhita 2
symptom relief 245
synergism 158
Synhexyl 234
- tail-flick 38
taste avoidance 193, 194
taste reactivity (TR) 193
tau protein 95
terpene 237, 242
terpenoid 236
 α -terpineol 16
Tetanus 9
 Δ^9 -tetrahydrocannabinol (Δ^9 -THC)
10, 23, 67, 100, 111, 113–115,
117, 118, 184, 187–192, 194,
195, 211, 231, 232, 235, 237,
239, 242–244, 253, 254, 256
tetrahydrocannabivarin (THC-V)
236, 242
Tetranabinex[®] 241, 243, 244, 251,
253, 254
therapeutic modulation of the
endocannabinoid system 215
therapeutic window 245, 256, 258
thin-layer chromatography (TLC)
241
tolerability 245, 255, 256, 258
tolerability profile 259
trabecular bone 202
trabecular bone density 203
transcription factor Ikaros 73
transforming growth factor- β 86
transgenic mouse 91
transplant rejection 37
- traumatic brain injury 30, 88
traumatic head injury 202
traumatic injury 87, 100
tremor 93, 94, 98, 252
trichome 237
TRPV1 173
tuberculosis 12
tumor necrosis factor- α (TNF- α)
13–15, 83, 85, 86, 93, 95, 97
tumor reduction 13
tyrosine hydroxylase 94
- UCM707 80, 157
ulcerative colitis 15
Unani Tibbi 6
URB532 157
URB597 157
urinary disorders 12
uterine receptivity 68
uterus 68
- vasoconstriction 87
VDM11 80, 157
Vedas 2
veterinary medicine 11
vijaya 4, 5
virodhamine 17, 26, 234
Visual Analogue Scale (VAS) 251–
253, 255, 257
voltage-sensitive ion channel 83
VR1 receptor 173
- WIN-55,212–2 29, 185, 187–189
withdrawal syndrome 209
working memory 112–114, 117
- Zend-Avesta 2
Zoroastrianism 2